Diagnostics firm Aqtual secured $31 million in funding to enhance development of a predictive test designed to forecast patient responses to rheumatoid arthritis drugs. The company aims to improve therapeutic decision-making by enabling personalized treatment plans based on biomarkers indicative of drug efficacy. This financing round will support clinical validation and commercialization efforts for its assay, addressing a critical need for tailoring rheumatoid arthritis therapies.